X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (90) 90
index medicus (90) 90
oncology (73) 73
female (64) 64
melanoma (62) 62
male (60) 60
middle aged (56) 56
adult (49) 49
aged (46) 46
melanoma - pathology (42) 42
skin neoplasms - pathology (33) 33
cancer (32) 32
malignant-melanoma (25) 25
prognosis (24) 24
neoplasm staging (23) 23
melanoma - drug therapy (21) 21
adolescent (19) 19
melanoma - mortality (19) 19
survival (19) 19
melanoma - immunology (18) 18
surgery (18) 18
disease-free survival (16) 16
immunotherapy (16) 16
skin neoplasms - drug therapy (16) 16
skin neoplasms - mortality (16) 16
treatment outcome (16) 16
care and treatment (15) 15
melanoma - surgery (15) 15
lymphatic metastasis (14) 14
melanoma - secondary (14) 14
retrospective studies (14) 14
aged, 80 and over (13) 13
metastasis (13) 13
abridged index medicus (12) 12
dermatology (12) 12
metastatic melanoma (12) 12
skin neoplasms - surgery (12) 12
melanoma - genetics (11) 11
melanoma - therapy (11) 11
animals (10) 10
child (10) 10
cutaneous melanoma (10) 10
expression (10) 10
follow-up studies (10) 10
immunology (10) 10
interferon-alpha - therapeutic use (10) 10
metastases (10) 10
analysis (9) 9
biopsy (9) 9
chemotherapy, adjuvant (9) 9
chemotherapy, cancer, regional perfusion (9) 9
dendritic cells (9) 9
lymph nodes - pathology (9) 9
melphalan (9) 9
melphalan - administration & dosage (9) 9
skin neoplasms - immunology (9) 9
survival analysis (9) 9
therapy (9) 9
cell biology (8) 8
clinical trials (8) 8
drug therapy (8) 8
health aspects (8) 8
medicine & public health (8) 8
melanoma - metabolism (8) 8
recurrence (8) 8
sarcoma (8) 8
skin neoplasms - therapy (8) 8
cancer vaccines - therapeutic use (7) 7
child, preschool (7) 7
combined modality therapy (7) 7
diagnosis (7) 7
patient outcomes (7) 7
skin cancer (7) 7
survival rate (7) 7
time factors (7) 7
antigens (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
experience (6) 6
genetic aspects (6) 6
high-risk melanoma (6) 6
hyperthermia, induced (6) 6
interleukin-2 (6) 6
leg (6) 6
lymph node excision (6) 6
medical research (6) 6
medicine, research & experimental (6) 6
melanoma - diagnosis (6) 6
mice (6) 6
neoplasm metastasis (6) 6
neoplasm recurrence, local - pathology (6) 6
peripheral-blood (6) 6
research (6) 6
risk factors (6) 6
skin neoplasms - genetics (6) 6
t cells (6) 6
t-lymphocytes - immunology (6) 6
vaccination (6) 6
young adult (6) 6
adjuvants, immunologic - therapeutic use (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 5639
  An important checkpoint in the progression of melanoma is the metastasis to lymph nodes. Here, to investigate the role of lymph node NK cells in disease... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 879 - 886
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 35, pp. 3441 - 3449
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF... 
PLACEBO | MODELS | ONCOLOGY | DOUBLE-BLIND | HAZARD | CURE FRACTION | MALIGNANT-MELANOMA | IPILIMUMAB | Rapid Communication
Journal Article
Journal Article
Journal Article
Nature Genetics, ISSN 1061-4036, 2009, Volume 41, Issue 8, pp. 909 - 914
Journal Article
Journal Article